Literature DB >> 10872568

Effects of pyridinium chlorochromate adulterant (urine luck) on testing for drugs of abuse and a method for quantitative detection of chromium (VI) in urine.

B D Paul1, K K Martin, J Maguilo, M L Smith.   

Abstract

Pyridinium chlorochromate (PCC) as an adulterant is popular for concealing drug-positive results. When 11-nor-delta9-THC-9-carboxylic acid (THC-acid) in urine was treated with 2 mmol/L of PCC (Cr6+ 104 microg/mL), 58-100% of the THC-acid was lost. The loss increased with decreasing pH and increasing reaction time (0-3 days). Free codeine and free morphine remained unaffected by PCC at pH within the physiological range of the urine (pH 5-7). At lower pH, the loss of free morphine varied from 0 to 100%. Amphetamine, methamphetamine, benzoylecgonine, and PCP remained unaffected by PCC when exposed to the oxidant for three days in urine pH of 3-7. Chromium (VI) from PCC in a urine solution was detected by a color reaction with 1,5-diphenylcarbazide (DPC). When the reagent was added to the urine, an immediate red-violet color appeared. The chromium-DPC complex showed a characteristic absorption peak at wavelength 544 nm with a shoulder at wavelength 575 nm. The ratio of absorption was used to identify the chromium compound. The concentration of chromium (VI) was determined by measuring absorption at wavelength 544 nm and was linear over 0.5-20 microg/mL. The limit of detection of the procedure was 0.37 microg/mL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10872568     DOI: 10.1093/jat/24.4.233

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  2 in total

1.  Immunoassays for drug screening in urine : Chances, challenges, and pitfalls.

Authors:  Harald Schütz; Alexandre Paine; Freidoon Erdmann; Günter Weiler; Marcel A Verhoff
Journal:  Forensic Sci Med Pathol       Date:  2006-06       Impact factor: 2.007

2.  Longitudinal analysis of health outcomes after exposure to toxics, Willits California, 1991-2012: application of the cohort-period (cross-sequential) design.

Authors:  Linda L Remy; Ted Clay
Journal:  Environ Health       Date:  2014-10-24       Impact factor: 5.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.